Premium
Renal function evaluation in an integrative cardio‐renal pharmacology model using Culex Empis® automated drug infusion system and radio telemetry
Author(s) -
Chen Yafei,
Brott David,
Bently Patricia,
Kamendi Harriet,
Campbell Pamela,
Kinter Lewis,
Bialecki Russell A
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.1059.28
Subject(s) - renal function , urology , medicine , inulin , pharmacokinetics , renal physiology , telemetry , pharmacology , kidney , clearance , chemistry , computer science , telecommunications , biochemistry
Recently we showed utility of a novel integrative pharmacology system (CUlex TElemetry: CUTE) that allows simultaneous evaluation of CNS/CV/Renal functions with automated blood sampling in the same rat. To evaluate potential risk of drug‐induced renal and cardiac dysfunction, or their bidirectional effects, a new procedure was developed for simultaneous estimation of heart and global renal function. Briefly, inulin‐FITC (2.5 mg/mL) and p‐aminohippuric acid (PAH; 40 mg/mL) were continuously co‐administered (i.v., 0.5 mL/hour) in conscious, unrestrained Han Wistar rats using Empis® automated drug infusion system combined with CUTE. Steady state was reached after 60 min, and 11 blood samples were collected over the next 3 days. Plasma clearance of inulin and PAH were determined using Fick's principle (renal clearance = infusion rate/plasma level). There were no significant differences in estimated glomerular filtration rate (eGFR) between plasma clearance (0.95 ± 0.05) vs. reference urinary clearance method (1.07 ± 0.14 mL/min/100g BW). Mean blood pressure (102.6 ± 3.54 mmHg) and heart rate (422.9 ± 8.26 bpm) were not altered by infusion of markers for 3 days. This new approach allows simple, rapid and reproducible evaluation of renal function with respect to traditional procedures, making it a useful model for preclinical cardio‐renal safety assessment.